Consun Pharmaceutical Group Toekomstige groei
Future criteriumcontroles 4/6
Consun Pharmaceutical Group zal naar verwachting groeien in winst en omzet met respectievelijk 14.9% en 13.5% per jaar. De winst per aandeel zal naar verwachting groeien met 14.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.1% zijn.
Belangrijke informatie
14.9%
Groei van de winst
14.4%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 10.8% |
Inkomstengroei | 13.5% |
Toekomstig rendement op eigen vermogen | 24.1% |
Dekking van analisten | Low |
Laatst bijgewerkt | 14 Oct 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story
Oct 02Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors
Sep 26Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
Jun 12Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30
May 12Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30
Jun 01Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet
May 04Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20
Apr 28Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20
Apr 07Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Aug 26Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly
Apr 21Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?
Mar 17Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative
Feb 19How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 29Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?
Jan 08Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly
Dec 18Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?
Nov 18Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 3,832 | 1,213 | N/A | 1,249 | 2 |
12/31/2025 | 3,352 | 1,056 | N/A | 1,098 | 2 |
12/31/2024 | 2,948 | 915 | N/A | 953 | 2 |
6/30/2024 | 2,739 | 836 | 833 | 915 | N/A |
3/31/2024 | 2,665 | 810 | 800 | 867 | N/A |
12/31/2023 | 2,590 | 785 | 766 | 819 | N/A |
9/30/2023 | 2,528 | 759 | 797 | 844 | N/A |
6/30/2023 | 2,466 | 734 | 828 | 869 | N/A |
3/31/2023 | 2,403 | 708 | 862 | 908 | N/A |
12/31/2022 | 2,340 | 683 | 896 | 948 | N/A |
9/30/2022 | 2,246 | 660 | 836 | 906 | N/A |
6/30/2022 | 2,152 | 636 | 776 | 865 | N/A |
3/31/2022 | 2,098 | 613 | 701 | 795 | N/A |
12/31/2021 | 2,045 | 590 | 627 | 726 | N/A |
9/30/2021 | 1,959 | 565 | 655 | 731 | N/A |
6/30/2021 | 1,874 | 541 | 683 | 737 | N/A |
3/31/2021 | 1,813 | 520 | 748 | 802 | N/A |
12/31/2020 | 1,753 | 499 | 813 | 867 | N/A |
9/30/2020 | 1,653 | 269 | 639 | 717 | N/A |
6/30/2020 | 1,553 | 39 | 465 | 567 | N/A |
3/31/2020 | 1,641 | 60 | 334 | 475 | N/A |
12/31/2019 | 1,728 | 80 | 203 | 383 | N/A |
9/30/2019 | 1,822 | 288 | 231 | 442 | N/A |
6/30/2019 | 1,916 | 496 | 259 | 501 | N/A |
3/31/2019 | 1,880 | 481 | 410 | 628 | N/A |
12/31/2018 | 1,844 | 465 | 561 | 754 | N/A |
9/30/2018 | 1,802 | 448 | 519 | 662 | N/A |
6/30/2018 | 1,760 | 430 | 476 | 570 | N/A |
3/31/2018 | 1,710 | 413 | N/A | 411 | N/A |
12/31/2017 | 1,660 | 396 | N/A | 252 | N/A |
9/30/2017 | 1,601 | 372 | N/A | 323 | N/A |
6/30/2017 | 1,541 | 347 | N/A | 393 | N/A |
3/31/2017 | 1,382 | 327 | N/A | 421 | N/A |
12/31/2016 | 1,223 | 308 | N/A | 449 | N/A |
9/30/2016 | 1,060 | 291 | N/A | 362 | N/A |
6/30/2016 | 896 | 274 | N/A | 275 | N/A |
3/31/2016 | 863 | 262 | N/A | 230 | N/A |
12/31/2015 | 831 | 250 | N/A | 184 | N/A |
9/30/2015 | 814 | 246 | N/A | 180 | N/A |
6/30/2015 | 798 | 242 | N/A | 175 | N/A |
3/31/2015 | 764 | 226 | N/A | 235 | N/A |
12/31/2014 | 731 | 211 | N/A | 295 | N/A |
9/30/2014 | 697 | 198 | N/A | 285 | N/A |
6/30/2014 | 664 | 185 | N/A | 275 | N/A |
3/31/2014 | 618 | 169 | N/A | 219 | N/A |
12/31/2013 | 572 | 153 | N/A | 164 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 1681 ( 14.9% per jaar) ligt boven de spaarquote ( 2.3% ).
Winst versus markt: De winst van 1681 ( 14.9% per jaar) zal naar verwachting sneller groeien dan de Hong Kong markt ( 11.6% per jaar).
Hoge groeiwinsten: De winst van 1681 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van 1681 ( 13.5% per jaar) zal naar verwachting sneller groeien dan de markt Hong Kong ( 7.8% per jaar).
Hoge groei-inkomsten: De omzet van 1681 ( 13.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 1681 zal naar verwachting over 3 jaar hoog zijn ( 24.1 %)